Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback